Fortune China's top 500 released, five pharmaceutical businesses occupy the top spot, the policy impact of the situation is beginning to emerge.

Guide: Under the influence of the policy, large commercial companies have increased their investment efforts, and the concentration of the industry has increased significantlyOn July !---- 27th, Fortune released the 2020 China 500 Rankings, a total of 18 pharmaceutical companies on the list, the overall list is not much, the specific list is as follows: among the 18 listed pharmaceutical companies, China Pharmaceuticals, China Resources ranked in the top three; China's top 500 pharmaceutical enterprises in the only loss-making enterprises; Baiyunshan Pharmaceuticals, Hengrui Pharmaceuticals ranked significantly; Nanjing Pharmaceuticals, East China Pharmaceuticals, China Pharmaceutical Health, Heavy Medicine Holdings, China Biological, Jiaxuan Pharmaceuticals, Shi Pharma Group, Renfu Pharmaceuticals ranked up, but the overall fluctuations are not large; Tianshili Pharmaceuticals, Yunnan White Medicine, Ruikang Pharmaceutical Group Co., Ltdranked lowerPharmaceutical circulation company, occupying the top of the list of 18 listed enterprises, the four major pharmaceutical circulation companies, occupy the top, in addition, the fifth-ranked Baiyunshan Pharmaceutical, its subsidiary Guangzhou Pharmaceutical Co., Ltdis the largest pharmaceutical circulation enterprises in southern China, in September 2019 Baiyunshan announced that the proposed spin-off of Guangzhou Pharmaceuticaltoris to Hong Kong stock listingIn other words, under the challenge of industry change and policy, leading pharmaceutical distribution companies still maintain a high growth rateThe "two-vote system" in 2017 has brought great impact on commercial companies with a relatively stable pattern, the original market pattern has been broken, a large number of small-scale circulation enterprises have gradually been out, while large commercial companies have increased their investment efforts to fill the gap in market share, and the concentration of the industry has been greatly increasedData show that in 2018, The main business income of the four leading national enterprises, China Pharmaceuticals, China Resources Pharmaceuticals and Kyushu Tong, accounted for 39.1% of the total size of the national pharmaceutical market in the same period, an increase of nearly 5 percentage points over 2017, and it is expected that by 2020, the proportion of the three giants of "National Pharmaceutical, China Resources and Pharmaceuticals" will reach 50%Sina-Pharmaceutical Holdings - Increased revenue of 3 in 2019 to 425.273 billion yuan, up 23.43 percent year-on-yearAccording to the annual report, this is mainly due to the growth of the pharmaceutical distribution business, pharmaceutical retail business and medical device business of China Pharmaceutical Holdings, and the growth of The Pharmaceutical Holdings of China's pharmaceutical market is higher than the average development of China's pharmaceutical marketAmong them, pharmaceutical distribution revenue was RMB337.316 billion, up 20.02% YoY, accounting for 78.18% of total revenueAccording to the annual report, the future Ofchina Pharmaceutical Holdings will optimize its main business, strengthen diversified business layout, focus on developing one-stop, one-piece supply chain service capabilities, promote win-win development with upstream pharmaceutical industry and downstream end customers, and screen suitable merger and acquisition targets in the pharmaceutical retail and medical device business areas, and explore new profit growth points through endogenous and extended two-wheel driveShanghai Pharma - Shanghai Pharma's operating income increased by 4 in 2019 to RMB186.566 billion, up 17.27% YoY, of which Shanghai Pharmaceutical Business Segment achieved operating income of RMB163.076 billion, up 16.80% YoY, and the main business contribution profit was RMB2.225 billion, up 26.75% YoYIn China's pharmaceutical business, Shanghai Pharma's acquisition of Sichuan Guojia has increased its influence in the southwestOn the other hand, with many multinational enterprises to achieve strategic cooperation, the east wind of the policy, under the impetus of heavy new drugs to achieve accelerated developmentIn addition, in the new business area is also stable progressIn 2019, the company's vaccine import business continued to maintain a leading and high growth trend, with business revenue of 3.14 billion yuan, up 103.9% YoY; China Resources Pharmaceuticals - The total annual revenue of China Resources Pharma in 2019 reached HK$204.45 billion, achieving solid growth Among them, pharmaceutical, pharmaceutical distribution, pharmaceutical retailing accounted for 15.0%, 81.7% and 3.2% respectively  China Resources Pharmaceuticals is accelerating the development of third-party logistics business, vigorously promote DTP, Run Pharmaceutical Mall, Run Pharmaceutical Cloud, such as innovative business models, to consolidate the pharmaceutical supply chain comprehensive solution providers of market leadership Kyushu Tong - increased 6 domestic largest private pharmaceutical circulation enterprises, Kyushu Tong, in 2019 to achieve annual operating income of 99.497 billion, up 14.19 percent year-on-year, net profit of 1.727 billion, up 28.79 percent year-on-year, revenue and net profit both achieved steady growth, performance is bright Guangzhou Baiyunshan Pharmaceuticals - The 55-year-old Guangmedicine Baiyunshan achieved operating income of 64.952 billion yuan in 2019, up 53.79 percent year-on-year, while total profit was 4.129 billion yuan, up 2.73 percent year-on-year In 2019, Guangzhou Pharmaceutical Co., Ltd., a leader in the commercial sector of Guangzhou Pharmaceutical Baiyunshan, seized the development opportunities of GPO and volume procurement in Guangshen and other places, focused on promoting medical institutions business, and achieved a large increase in the proportion of GPO orders in hospitals Cechilin Pharmaceuticals strengthens the service of Chinese medicine's intelligent fried, medicinal medicine identification and other special Chinese medicine drink tablets, and promotes the sales of Chinese medicine tablets in medical institutions to increase significantly At the same time, Guang medicine Baiyunshan to further expand retail stores and regional coverage, layout DTP pharmacy At the end of 2019, the total number of retail stores under the pharmaceutical company reached 75, and sales grew at a faster pace Zezhilin Pharmaceuticals to build a Chinese medicine specialty outpatient "national medicine hall", and actively explore the development of "medicine and medicine" Chinese medicine chain model In addition, in order to optimize the capital structure, improve the quality of operations and reduce operational risks, pharmaceutical companies have carried out the securitization of accounts receivable assets, and successfully set up the first phase of asset support special plan in December 2019 By the end of 2019, the cumulative asset sales of pharmaceutical companies' asset securitization amounted to RMB1,889 million In September 2019, Guangpharma Baiyunshan officially launched the company's spin-off to overseas listing related work to further broaden the financing channels of pharmaceutical companies